Company intelligence / Profile preview

Polpharma Biologics

Ownership: Private
Employees: ~1299
Development stage: Commercial

Overview

Polpharma Biologics has achieved regulatory approvals in both the US and Europe for Tyruko®—the first natalizumab biosimilar for relapsing forms of multiple sclerosis. Its vedolizumab biosimilar candidate has demonstrated PK/PD comparability to Entyvio® in clinical studies. The pipeline also includes preclinical programs targeting oncology and immunology indications.

Therapeutic areas: GastroenterologyOncologyImmunologyNeurology
Modalities: BiosimilarsMonoclonal antibodies (mAbs)Biological products
Industry: Biotech

Drug pipeline

6 assets

PB018

5 more assets in the full pipeline.

Request access →

Partnerships

Sandoz – commercialization partner for Tyruko® in Europe and the US.

Beyond the preview

Go deeper on Polpharma Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polpharma Biologics.

Explore the full profile